March 2026
PTSD
What March 2026's 10 new studies found, synthesized from the papers below. All PTSD research →
The synthesis
Synthesized from 10 studies in the library · AI-generated, grounded in the abstracts below
Found by searching the library for PTSD, post-traumatic stress disorder, traumatic stress, then ranked by relevance.
Research in March 2026 found that MDMA-assisted therapy reduces PTSD symptoms (moderate-to-large effect sizes) and increases response/remission rates, though evidence certainty is low due to blinding and expectancy issues. Ketamine also shows efficacy for PTSD, with emerging mechanistic insights, and ibogaine was associated with long-term symptom improvement in veterans linked to brain network reorganization. However, most evidence is limited by small samples, high risk of bias, and lack of active comparators.
Confidence in the evidence
Low-Moderate- Multiple meta-analyses (27849, 25094) and reviews (24928) consistently show positive effects for MDMA and ketamine, but sample sizes are small (e.g., 286 participants in 27849).
- Design quality is moderate: several RCTs exist, but high risk of bias from functional unblinding and expectancy effects is noted across studies (27849, 25094, 25110).
- Results are directionally consistent for MDMA and ketamine, but ibogaine evidence is from a single observational study (27281) with no control group.
- GRADE ratings assign low certainty to MDMA findings (27849, 25094), and reviews highlight gaps in safety monitoring and generalizability (25110).
How we rate confidence
Confidence reflects the strength of the underlying evidence, not whether the result is favorable. It weighs the number and size of studies, their design (randomized trials count for more than observational or single-case work), how consistently they point the same way, and their risk of bias.
Tiers run from Insufficient to High. High is rare in this field: small, early, or open-label studies land lower even when their direction is encouraging.
Evidence by study
Direction is each study's finding relative to your question: Supports, Opposes, No effect, Mixed, or Unclear.
| Study | Design | Sample size | Direction | Finding |
|---|---|---|---|---|
| A living systematic review, meta-analysis, and open data resource of trials of MDMA-assisted therapy for PTSD 2026 | living systematic review and meta-analysis | 286 | Supports | MDMA-assisted therapy showed greater reduction in PTSD symptoms (Hedges' g = -0.71) and higher response (RR=1.35) and remission (RR=2.25) rates compared to control, but evidence certainty was low due to expectancy and unblinding issues. |
| Underlying Mechanisms of the Treatment Efficacy of (R, S)‐Ketamine for Post‐Traumatic Stress Disorder and Depression: A Review 2026 | review | Supports | Ketamine and its stereoisomers show efficacy for PTSD and comorbid depression, with mechanisms involving serotonin signaling in the dorsal raphe nucleus and activation of the prelimbic–dorsal raphe nucleus circuit. | |
| Ibogaine is associated with reorganization of high-beta brain networks in veterans with post-traumatic stress disorder 2026 | observational | 30 | Supports | A single dose of ibogaine was associated with PTSD symptom improvement up to 12 months later, correlated with a posterior shift in high-beta brain networks. |
| State of the Science: MDMA‐assisted psychotherapy for the treatment of posttraumatic stress disorder 2026 | review | Supports | MDMA-assisted psychotherapy shows promising outcomes in RCTs but was declined by the FDA in 2024 due to insufficient evidence; key limitations include blinding challenges, lack of active comparators, and limited sample generalizability. | |
| Efficacy of 3,4-methylenedioxymethamphetamine (MDMA)-assisted therapy for posttraumatic stress disorder: A systematic review and meta-analysis of clinical and functional outcomes 2026 | systematic review and meta-analysis | 298 | Supports | MDMA-AT was associated with reductions in PTSD symptom severity (SMD = -1.19), dissociative symptoms, and improved functioning, but no clear benefit for depressive symptoms; most studies had high risk of bias. |
| Efficacy and risks of psychedelics in treatment of posttraumatic stress disorder: A systematic review 2026 | systematic review | Supports | MDMA and ketamine IV have the greatest support for efficacy in PTSD, with improvements under supervision and generally good tolerability, but caution is needed due to expectancy effects and inadequate blinding. | |
| Flashbacks Through Time: Historical Development and Current Use of the Term "Flashback" in Psychedelic and Post-Traumatic Stress Disorder Research. 2026 | theoretical | Unclear | This paper reviews the historical development and current use of the term 'flashback' in psychedelic and PTSD research, but does not report empirical findings on PTSD treatment. | |
| Toward dimensional body consciousness impairments in post-traumatic stress disorder and its dissociative subtype: A predictive processing approach. 2026 | theoretical | Unclear | This review introduces a predictive processing framework for body consciousness impairments in PTSD and its dissociative subtype, but does not report empirical treatment outcomes. | |
| Brain State Dynamics in Ketamine-Induced Dissociation Resemble Those in Posttraumatic Stress Disorder. 2026 | observational | 108 | Mixed | Ketamine-induced dissociation in healthy volunteers resembled brain state dynamics in PTSD patients, and posttreatment reduction in DMN meta-state dominance correlated with decreased dissociative symptoms in PTSD. |
| Ketamine-Prazosin Combined Pharmacotherapy in Post-Traumatic Stress Disorder and Alcohol Use Disorder: Targeting Complementary Neurobiological Mechanisms. 2026 | theoretical | Unclear | This paper proposes a rationale for ketamine-prazosin combination pharmacotherapy for comorbid PTSD and alcohol use disorder, but notes it is untested in clinical trials. |
MDMA-assisted therapy showed greater reduction in PTSD symptoms (Hedges' g = -0.71) and higher response (RR=1.35) and remission (RR=2.25) rates compared to control, but evidence certainty was low due to expectancy and unblinding issues.
living systematic review and meta-analysis Sample size: 286
Ketamine and its stereoisomers show efficacy for PTSD and comorbid depression, with mechanisms involving serotonin signaling in the dorsal raphe nucleus and activation of the prelimbic–dorsal raphe nucleus circuit.
review
A single dose of ibogaine was associated with PTSD symptom improvement up to 12 months later, correlated with a posterior shift in high-beta brain networks.
observational Sample size: 30
MDMA-assisted psychotherapy shows promising outcomes in RCTs but was declined by the FDA in 2024 due to insufficient evidence; key limitations include blinding challenges, lack of active comparators, and limited sample generalizability.
review
MDMA-AT was associated with reductions in PTSD symptom severity (SMD = -1.19), dissociative symptoms, and improved functioning, but no clear benefit for depressive symptoms; most studies had high risk of bias.
systematic review and meta-analysis Sample size: 298
MDMA and ketamine IV have the greatest support for efficacy in PTSD, with improvements under supervision and generally good tolerability, but caution is needed due to expectancy effects and inadequate blinding.
systematic review
This paper reviews the historical development and current use of the term 'flashback' in psychedelic and PTSD research, but does not report empirical findings on PTSD treatment.
theoretical
This review introduces a predictive processing framework for body consciousness impairments in PTSD and its dissociative subtype, but does not report empirical treatment outcomes.
theoretical
Ketamine-induced dissociation in healthy volunteers resembled brain state dynamics in PTSD patients, and posttreatment reduction in DMN meta-state dominance correlated with decreased dissociative symptoms in PTSD.
observational Sample size: 108
This paper proposes a rationale for ketamine-prazosin combination pharmacotherapy for comorbid PTSD and alcohol use disorder, but notes it is untested in clinical trials.
theoretical
Points of agreement
- MDMA-assisted therapy consistently shows reductions in PTSD symptoms across multiple meta-analyses and reviews.
- Ketamine is supported as an efficacious treatment for PTSD, with converging mechanistic evidence.
- All reviews highlight significant methodological limitations, including expectancy effects, functional unblinding, and high risk of bias.
Conflicts
- One meta-analysis (27849) found a moderate effect (g = -0.71) while another (25094) found a larger effect (SMD = -1.19), possibly due to different inclusion criteria or analysis methods.
- Ibogaine evidence is from a single observational study (27281) with no control group, contrasting with the more robust RCT evidence for MDMA and ketamine.
Gaps
- Durability of treatment effects beyond short-term follow-up is not well established.
- Lack of active comparator conditions and head-to-head comparisons between psychedelics.
- Limited sample generalizability due to small, homogeneous populations.
- Inadequate safety monitoring and lack of data on long-term adverse effects.
- No RCTs for psilocybin or LSD in PTSD, as noted in one review (24928).